一例替尔泊肽（Tirzepatide）超说明书使用致严重胃肠道反应、低血糖与冠状动脉非阻塞性心肌梗死（MINOCA）

吴 敏杰, 王 明晶
义乌稠州医院心内科

摘要


本文报道一例19岁女性因自行超说明书使用替尔泊肽（Tirzepatide）注射液减重，导致严重胃肠道反应、进食障碍及低血糖，继而引发胸痛、肌钙蛋白升高，冠脉造影排除阻塞性病变，最终诊断为“冠状动脉非阻塞性心肌梗死（MINOCA）”的病例。旨在提醒临床医生关注GLP-1受体激动剂类药物的胃肠道不良反应及其潜在心血管风险。

关键词


替尔泊肽；MINOCA；低血糖；心肌梗死；减重药物不良反应

全文:

PDF


参考


[1]Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *N Engl J Med*. 2021;385(6):503-515.

[2]Kapitza C, Dahl K, Jacobsen JB, et al. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. *Diabetologia*. 2017;60(8):1390-1399.

[3]Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016;375(19):1834-1844.

[4]Smits MM, Van Raalte DH. Safety of Semaglutide. *Front Endocrinol (Lausanne)*. 2021;12:645563.

[5]Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. *Eur Heart J*. 2017;38(3):143-153.

[6]Goyal A, Mahaffey KW, Garg J, et al. Prognostic significance of hypoglycemia in acute coronary syndromes. *J Am Coll Cardiol*. 2017;70(6):750-758.

[7]Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. *Diabetes*. 2014;63(5):1738-1747.

[8]Basso C, Calabrese F, Angelini A, et al. Classification and histological, molecular, and ultrastructural features of myocardial injury in COVID-19. *J Am Coll Cardiol*. 2021;77(18):2266-2275.

[9]Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2019;139(18):e891-e908.


Refbacks

  • 当前没有refback。